AMG 176, a selective MCL1 inhibitor, is effective in hematologic cancer models alone and in combination with established therapies

Sean Caenepeel, Sean P. Brown, Brian Belmontes, Gordon Moody, Kathleen S. Keegan, Danny Chui, Douglas A. Whittington, Xin Huang, Leszek Poppe, Alan C. Cheng, Mario Cardozo, Jonathan Houze, Yunxiao Li, Brian Lucas, Nick A. Paras, Xianghong Wang, Joshua P. Taygerly, Marc Vimolratana, Manuel Zancanella, Liusheng ZhuElaina Cajulis, Tao Osgood, Jan Sun, Leah Damon, Regina K. Egan, Patricia Greninger, Joseph D. McClanaghan, Jianan Gong, Donia Moujalled, Giovanna Pomilio, Pedro Beltran, Cyril H. Benes, Andrew W. Roberts, David C. Huang, Andrew Wei, Jude Canon, Angela Coxon, Paul E. Hughes

Research output: Contribution to journal › Article › peer-review

286 Scopus citations

Fingerprint

Dive into the research topics of 'AMG 176, a selective MCL1 inhibitor, is effective in hematologic cancer models alone and in combination with established therapies'. Together they form a unique fingerprint.

Medicine & Life Sciences